| Drug Name: | Brimonidine (59803-98-4) |
|---|---|
| PubChem ID: | 2435 |
| SMILES: | C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br |
| InchiKey: | XYLJNLCSTIOKRM-UHFFFAOYSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Agonists, Adrenergic alpha-2 Receptor Agonists, Adrenergic alpha-Agonists, Antihypertensive Agents, Cardiovascular Agents, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 292.14 |
| LogP | : | 1.7634 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 62.2 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Platelet Aggregation | Alpha-2A adrenergic receptor (P08913) | Alpha 2-Adrenoceptor(epinephrine and UK 14304)-mediated platelet aggregation could represent a better marker than inhibition of adenylate cyclase to assess functional changes of the receptor in depression [ ADR Type 1 ] | Alpha 2-adrenoceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression Effect of long-term cyclic antidepressant drug treatment |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category